David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$436M |
| 2 |
AbbVie
ABBV
|
+$407M |
| 3 |
Johnson & Johnson
JNJ
|
+$295M |
| 4 |
Gilead Sciences
GILD
|
+$267M |
| 5 |
Starbucks
SBUX
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$407M |
| 2 |
Booking.com
BKNG
|
+$400M |
| 3 |
Citigroup
C
|
+$314M |
| 4 |
SHPG
Shire pic
SHPG
|
+$276M |
| 5 |
PayPal
PYPL
|
+$257M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.04% |
| 2 | Healthcare | 13.44% |
| 3 | Consumer Discretionary | 13.38% |
| 4 | Financials | 7.19% |
| 5 | Industrials | 6.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2926
CALL
American States Water
AWR
$3.56B
| $535K | ﹤0.01% |
7,500
+3,500
| +88% | +$240K |
|
2927
MetLife
MET
$61.3B
| $535K | ﹤0.01% |
12,562
-8,207
| -40% | -$363K |
|
2928
STAAR Surgical
STAA
$1.15B
| $535K | ﹤0.01% |
15,662
-30,931
| -66% | -$1.09M |
|
|
GBT
2929
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $535K | ﹤0.01% |
10,100
| – | – |
|
|
FTSI
2930
DELISTED
FTS International, Inc. Common Stock
FTSI
| $534K | ﹤0.01% |
2,670
+633
| +31% | +$113K |
|
2931
Primis Financial Corp
FRST
$400M
| $532K | ﹤0.01% |
36,330
+134
| +0.4% | +$2.02K |
|
2932
CALL
Ventas
VTR
$48B
| $530K | ﹤0.01% |
8,300
-1,700
| -17% | -$106K |
|
|
VG
2933
DELISTED
Vonage Holdings Corporation
VG
| $528K | ﹤0.01% |
52,619
+32,443
| +161% | +$311K |
|
2934
PUT
Oshkosh
OSK
$9.72B
| $526K | ﹤0.01% |
7,000
-2,900
| -29% | -$214K |
|
|
CISN
2935
DELISTED
Cision Ltd. Ordinary Share
CISN
| $526K | ﹤0.01% |
38,163
-22,151
| -37% | -$285K |
|
2936
Sonida Senior Living
SNDA
$1.91B
| $525K | ﹤0.01% |
8,778
+2,215
| +34% | +$201K |
|
2937
VSE Corp
VSEC
$6.37B
| $525K | ﹤0.01% |
16,619
-5,543
| -25% | -$180K |
|
|
EMWP
2938
DELISTED
Eros Media World PLC
EMWP
| $523K | ﹤0.01% |
2,858
+1,388
| +94% | +$267K |
|
|
KSU
2939
PUT
DELISTED
Kansas City Southern
KSU
| $522K | ﹤0.01% |
4,500
| – | – |
|
2940
Braskem
BAK
$590M
| $521K | ﹤0.01% |
20,161
| – | – |
|
|
XRN
2941
Chiron Real Estate Inc
XRN
$494M
| $521K | ﹤0.01% |
10,619
+8,610
| +429% | +$424K |
|
2942
CALL
Quaker Houghton
KWR
$2.83B
| $521K | ﹤0.01% |
2,600
| – | – |
|
|
CNCE
2943
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $521K | ﹤0.01% |
43,157
-915
| -2% | -$13.5K |
|
|
POLY
2944
PUT
DELISTED
Plantronics, Inc.
POLY
| $521K | ﹤0.01% |
+11,300
| New | +$493K |
|
2945
Celldex Therapeutics
CLDX
$3.19B
| $520K | ﹤0.01% |
105,681
+100,792
| +2,062% | +$530K |
|
2946
Universal Logistics Holdings
ULH
$505M
| $520K | ﹤0.01% |
26,401
-6,513
| -20% | -$135K |
|
2947
CALL
Grand Canyon Education
LOPE
$3.88B
| $515K | ﹤0.01% |
4,500
| – | – |
|
2948
Red Robin
RRGB
$191M
| $515K | ﹤0.01% |
+17,907
| New | +$553K |
|
2949
Qualys
QLYS
$6.11B
| $512K | ﹤0.01% |
+6,189
| New | +$515K |
|
2950
SolarEdge
SEDG
$2.04B
| $512K | ﹤0.01% |
13,580
-49,327
| -78% | -$1.97M |
|
Similar funds
David Shaw's Q1 2019 Portfolio in Review
As of Q1 2019, David Shaw held 4,169 positions worth $77.4B, up 6.6% from $72.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
David Shaw withdrew a net $6.74B in Q1 2019, closing 617 positions and reducing 1,599 holdings. Its most notable exit was Shire pic, an estimated $276M position sold in full.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, David Shaw opened a new position in Lyft worth $159M.
- David Shaw's largest Q1 2019 buy was Lyft: 2,245,851 shares worth $159M.
- David Shaw added most to Pfizer in Q1 2019, an estimated $436M increase.
- David Shaw's biggest Q1 2019 reduction was Bristol-Myers Squibb, cutting an estimated $407M.
- David Shaw fully exited Shire pic in Q1 2019, selling an estimated $276M.
- David Shaw's ten largest holdings make up 9% of its $77.4B portfolio in Q1 2019.
- David Shaw opened 447 new positions and closed 617 in Q1 2019.
- David Shaw's portfolio value rose 6.6% quarter-over-quarter to $77.4B.
Based on D.E. Shaw & Co's 13F filing for Q1 2019, filed 15 May 2019.